3 results
Approved WMOCompleted
To increase progression-free survival at 3 months.
Approved WMOCompleted
Primary Objective:The primary objective is to assess the safety and tolerability of BMS-986179 administered alone and/or in combination with nivolumab.Secondary objectives:* To characterize the PD activity of BMS-986179 administered alone and in…
Approved WMOCompleted
The purpose of this prospective post market observational pilot study is to evaluate the effect of DRG stimulation in the management of chronic discogenic pain in subjects who are refractory to other available treatments. Selected subjects will not…